If history is any guide, including the results of similar litigation brought by Novo against generic drug manufacturers, such litigation will most likely end in a settlement, with minimal if any negative consequences for Hims
Regulatory and Safety Oversight Safety Monitoring: AI can assist in monitoring and predicting potential safety issues related to GLP-1 receptor agonists, helping regulatory bodies ensure safer treatments
An oral GLP-1/amylin agonist named oral amycretin (Novo Nordisk) is also in phase 1 development
Injection Route SubQ (subcutaneous) is the most accessible and practical
Individual factors including concentration used, baseline skin condition, age, lifestyle, and complementary skincare significantly affect benefit retention creating substantial variation in personal outcomes requiring experimentation for determining optimal individual approach
10.1016/j.trsl.2017.11.001 56 SingerM.DeutschmanC